Metrikler
Yayın
33
Açık Erişim
7
BM Sürdürülebilir Kalkınma Amaçları
Araştırma Alanları
Sağlık Bilimleri
Makaleler
Tümü (30)
SCI-E, SSCI, AHCI (20)
SCI-E, SSCI, AHCI, ESCI (23)
ESCI (3)
Scopus (26)
TRDizin (12)
2025
20251. FOLFIRINOX: The Best Adjuvant Treatment for Ampullary Adenocarcinoma? A Multicenter Study by the Turkish Oncology Group (TOG)
Kalem A., Kus T., Sahin T. K., DİZDAR Ö., Efil S. C., Sendur M. A. N., et al.
Cancers
, cilt.17, sa.17, 2025 (SCI-Expanded)
2025
20252. Association of TILs and HER2-low status with pathological response in triple-negative breast cancer
Deliktaş Onur İ., Kurukafa D., AĞYOL Y., Firat H. G., Sertesen Çamöz E., Türkel A., et al.
Medicine (United States)
, cilt.104, sa.33, 2025 (SCI-Expanded)
2025
20253. Comparison of Frontline FOLFIRINOX with Fluorouracil-Based and Gemcitabine-Based Chemotherapies in Metastatic Ampullary Adenocarcinoma: A Multicenter Study by the Turkish Oncology Group (TOG)
Kalem A., Kus T., Gokcek S., ÜNEK İ. T., Sahin T. K., DİZDAR Ö., et al.
Journal of Clinical Medicine
, cilt.14, sa.16, 2025 (SCI-Expanded)
2025
20254. Real-World Treatment Efficacy of Ribociclib or Palbociclib Plus Fulvestrant in Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Turkish Oncology Group (TOG) Study
Kahraman S., Erul E., GÜMÜŞAY Ö., GÜVEN D. C., AKSOY S., BAŞARAN G., et al.
Clinical Breast Cancer
, cilt.25, sa.5, 2025 (SCI-Expanded)
2025
20255. Hormon reseptörü pozitif, HER2 negatif metastatik meme kanseri tanısıyla ribosiklib veya palbosiklib ile letrozol kombinasyon tedavisi verilen hastalarda HER2-düşük ekspresyonunun önemi
kahraman s., Hizal M., Gumusay O., Basaran G., Seyyar M., Sahin E., et al.
Turkish Journal of Clinics and Laboratory
, cilt.16, sa.2, ss.255-262, 2025 (Hakemli Dergi)
2025
20256. Clinicopathological Features and Survival Outcomes of Colorectal Cancer Patients Under 40 Years: A 20-Years Single-Center Experience
Kaan A., Demircan N. C., ÖZGÜR S. Ş., AKYOL T. B., majıdova n., Kocaaslan E., et al.
Uluslararası Hematoloji-Onkoloji Dergisi
, cilt.35, sa.2, ss.104-111, 2025 (SCI-Expanded, Scopus, TRDizin)
2025
20257. Metastatik Kolorektal Kanser Tedavisinde Regorafenib Etkinliğini Etkileyen Prognostik Faktörler
SEVER N., bayoglu i. v.
Namık Kemal Tıp Dergisi
, cilt.13, sa.2, ss.170-177, 2025 (Hakemli Dergi)
2025
20258. Evaluation of Pancreatic Atrophy in Patients with Hepatocellular Carcinoma Receiving Sorafenib Treatment
Kaan A., Zengin G., majıdova n., SEVER N., Ergelen R., Köstek O., et al.
Eurasian Journal of Medical Investigation
, cilt.9, sa.1, ss.29-35, 2025 (Hakemli Dergi)
2025
20259. The Impact of Progesterone Receptor Status on Survival Outcomes in Metastatic Breast Cancer Patients Treated with First-Line CDK4/6 Inhibitors
Guliyev M., Güren A. K., Özge E., Çolak R., Majidova N., Alkan Şen G., et al.
Cancers
, cilt.17, sa.4, 2025 (SCI-Expanded)
2025
202510. Lung Immune Prognostic Index (LIPI): Prognostic predictor for patients with extensive-stage small-cell lung cancer
Majidova N., Seyyar M., Guren A. K., Kocaaslan E., Kircali M. F., Sever N., et al.
Marmara Medical Journal
, cilt.38, sa.1, ss.24-28, 2025 (ESCI)
2025
202511. The Effect of Systemic Inflammation and Clinicopathologic Features on Survival in Malignant Pleural Mesothelioma: A Multicenter Analysis
SEVER N., Yıldırım S., Gurbuz A. F., Karakaş Kılıç D., Zeynelgil E., Altintaş Y. E., et al.
Medicina (Lithuania)
, cilt.61, sa.1, 2025 (SCI-Expanded)
2024
202412. Bevacizumab versus aflibercept with FOLFIRI after FOLFOX and bevacizumab in RAS mutant metastatic colon cancer a Turkish oncology group study
Sekmek S., Ozsan Çelebi S. N., Bayram D., Erol C., Kos F. T., Sendur M. A. N., et al.
Scientific Reports
, cilt.14, sa.1, 2024 (SCI-Expanded, Scopus)
2024
202413. Efficacy of cumulative cisplatin dose on survival in patients with locally advanced cervical cancer treated with definitive chemoradiotherapy: multicenter study by Turkish Oncology Group
AKYILDIZ A., GÜLTEKİN M., YİĞİT E., Demir E., Ismayilov R., Ahmed M., et al.
International Journal of Gynecological Cancer
, cilt.34, sa.9, ss.1359-1365, 2024 (SCI-Expanded)
2024
202414. HER2 exon 20 mutant non-small cell lung cancer with complete remission of intracranial metastases with trastuzumab deruxtecan: A case report
Güren A. K., KOCAASLAN E., AĞYOL Y., Majidova N., Sever N., EREL P., et al.
Anti-Cancer Drugs
, cilt.35, sa.8, ss.769-773, 2024 (SCI-Expanded)
2024
202415. Total Neoadjuvant Therapy Versus Neoadjuvant Chemoradiation for Locally Advanced Rectal Cancer: A Multi-Institutional Real-World Study
Şenocak Taşçı E., Mutlu A. U., Saylık O., ÖLMEZ Ö. F., BİLİCİ A., Sünger E., et al.
Cancers
, cilt.16, sa.18, 2024 (SCI-Expanded)
2024
202416. Evaluation of sarcopenia-associated survival in breast cancer with computed tomography-based pectoral muscle area measurements
KUZAN B. N., MAJIDOVA N., ILGIN C., ARSLAN H., KURŞUN M., ÖZGÜVEN S., et al.
MARMARA MEDICAL JOURNAL
, cilt.37, sa.2, ss.178-184, 2024 (ESCI)
2024
202417. The Role of Immune-Inflammation Biomarkers to Predict the Response of Nivolumab in Second Line Treatment of Advanced Stage Non-Small Cell Lung Cancer
Ozkul O., Sahin E., Cabuk D., SEVER N., majıdova n., bayoglu i. v., et al.
Eurasian Journal of Medical Investigation
, cilt.8, sa.1, ss.58-66, 2024 (Hakemli Dergi)
2024
202418. Efficacy and Safety of Ixabepilone in Metastatic Breast Cancer After Multiple Treatments: Analysis Based on Real-World Data
Akdağ G., Alan Ö., Doğan A., Yildirim S., Kinikoğlu O., Majidova N., et al.
Journal of Oncological Science
, cilt.10, sa.2, ss.89-96, 2024 (Scopus)
2024
202419. The prognostic factors in patients with advanced hepatocellular carcinoma: impact of treatment sequencing
KÖSTEK O., DEMİREL A., Hacıoğlu M. B., TAŞTEKİN D., KARABULUT S., Gündogdu A., et al.
Journal of Chemotherapy
, cilt.36, sa.7, ss.613-621, 2024 (SCI-Expanded, Scopus)
2024
202420. Systemic Inflammation Response Index and Pan-Immune-Inflammation Value: Prognostic Significance in Metastatic Melanoma
Majidova N., Kircali M. F., Güren A. K., Sever N., KOCAASLAN E., AĞYOL Y., et al.
Journal of Oncological Science
, cilt.10, sa.3, ss.144-149, 2024 (Scopus, TRDizin)
2024
202421. Prognostic Factors Associated with Resected Osteosarcoma: Efficacy of Adjuvant Setting, Real-World Experience
Majidova N., ŞİMŞEK F., Biter S., YASLIKAYA Ş., Seyyar M., DUYGULU M. E., et al.
UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi
, cilt.34, sa.1, ss.20-27, 2024 (SCI-Expanded, Scopus, TRDizin)
2023
202322. PNI as a Potential Add-On Biomarker to Improve the IMDC Intermediate Prognostic Score
BAYOĞLU İ. V., Hüseynov J., Topal A., Sever N., Majidova N., Çelebi A., et al.
Journal of Clinical Medicine
, cilt.12, sa.19, 2023 (SCI-Expanded)
2023
202323. Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer
KAHRAMAN S., ERUL E., Seyyar M., GÜMÜŞAY Ö., Bayram E., Demirel B. C., et al.
FUTURE ONCOLOGY
, cilt.19, ss.727-736, 2023 (SCI-Expanded)
2023
202324. Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy
Karacin C., Oksuzoglu B., Demirci A., KESKİNKILIÇ M., Baytemür N. K., Yılmaz F., et al.
BMC cancer
, cilt.23, sa.1, ss.136, 2023 (SCI-Expanded)
2023
202325. Prognostic Significance of Mucinous Histology in Metastatic Colorectal Cancer Patients Treated with Regorafenib
ARIKAN R., Üstün H. S., Demircan N. C., Işik S., Telli T. A., Yaşar A., et al.
Journal of Oncological Science
, cilt.9, sa.2, ss.53-61, 2023 (Scopus, TRDizin)
2022
202226. Clinical outcomes of cyclin-dependent kinase 4-6 (CDK 4-6) inhibitors in patients with male breast cancer: A multicenter study
YILDIRIM H. Ç., MUTLU E., Chalabiyev E., Ozen M., KESKİNKILIÇ M., ÖN S., et al.
BREAST
, cilt.66, ss.85-88, 2022 (SCI-Expanded, Scopus)
2022
202227. Impact of Skeletal Muscle Measurements by Chest Computed Tomography on Survival and Postoperative Complications in Patients with Soft Tissue Sarcoma
AKIN TELLİ T., BUĞDAYCI O., Alan O., Sariyar N., Isik S., Arikan R., et al.
Nutrition and Cancer
, cilt.74, sa.7, ss.2499-2507, 2022 (SCI-Expanded)
2022
202228. Varicella-Zoster Virus Infection and Brivudine Therapy: Unexpected Response in Sarcoma Patient
KÖSTEK O., Sari M., BAYOĞLU İ. V.
EURASIAN JOURNAL OF MEDICINE AND ONCOLOGY
, cilt.6, sa.2, ss.182-185, 2022 (ESCI)
2014
201429. The clinical and pathological features of 133 colorectal cancer patients with brain metastasis: a multicenter retrospective analysis of the Gastrointestinal Tumors Working Committee of the Turkish Oncology Group (TOG)
TANRIVERDİ Ö., Kaytan-Saglam E., Ulger S., Bayoglu İ. V., Turker I., Ozturk-Topcu T., et al.
MEDICAL ONCOLOGY
, cilt.31, sa.9, 2014 (SCI-Expanded)
2014
201430. Sunitinib for Patients with Metastatic Non-clear Cell Renal Cell Carcinoma: A Multicenter Retrospective Turkish Oncology Group Trial
Yildiz I., Ekenel M., Akman T., Kocar M., UYSAL M., Kanitez M., et al.
ANTICANCER RESEARCH
, cilt.34, sa.8, ss.4329-4334, 2014 (SCI-Expanded)
Hakemli Bilimsel Toplantılarda Yayımlanmış Bildiriler
2015
20151. Breast cancer subtypes and the risk of distant relapse after breast conserving surgery or mastectomy: An Anatolian Society of Medical Oncology study.
Kaplan M. A., Urakci Z., Uncu D., Dane F., Ozkan M., Akman T., et al.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, Amerika Birleşik Devletleri, 29 Mayıs - 02 Haziran 2015, cilt.33, (Özet Bildiri)